Verano Holdings (VRNO) Change in Receivables (2021 - 2026)
Verano Holdings' (VRNO) quarterly Change in Receivables came in at $1.7 million in Q1 2026, little changed year-on-year from $1.7 million in Q1 2025, and up 226.99% on a QoQ basis from -$1.3 million in Q4 2025.
Verano Holdings (VRNO) Change in Receivables (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Change in Receivables data on file, last reported at $1.7 million in Q1 2026.
- On a quarterly basis, Change in Receivables changed 0.41% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was -$5.3 million, a 541.98% decrease from a year earlier, with the FY2025 full-year figure at -$5.4 million, down 295.01% from the prior year.
- Change in Receivables for Q1 2026 stood at $1.7 million, up from -$1.3 million in the prior quarter.
- Over the last five years, Change in Receivables for VRNO reached as high as $9.6 million in Q2 2023 and fell as low as -$7.7 million in Q2 2025.
- Historically, Change in Receivables has averaged $1.2 million across 5 years, with a median of $1.7 million in 2026.
- Across the five-year window, Change in Receivables surged 520.82% in 2023 and sank 522.33% in 2025, its largest moves.
- Year by year, Change in Receivables stood at $1.2 million in 2022, then surged by 351.58% to $5.6 million in 2023, then sank by 199.18% to -$5.5 million in 2024, then soared by 75.75% to -$1.3 million in 2025, then surged by 226.99% to $1.7 million in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were $1.7 million in Q1 2026, -$1.3 million in Q4 2025, and $2.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn | 1.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.70 Mn |
| Mar 31, 2026 | 1.70 Mn |
| Dec 31, 2025 | -1.34 Mn |
| Dec 31, 2025 | -1.34 Mn |
| Sep 30, 2025 | 2.01 Mn |
| Sep 30, 2025 | 2.01 Mn |
| Jun 30, 2025 | -7.72 Mn |
| Jun 30, 2025 | -7.72 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | -5.53 Mn |
| Dec 31, 2024 | -5.53 Mn |
| Sep 30, 2024 | 3.22 Mn |
| Sep 30, 2024 | 3.22 Mn |
| Jun 30, 2024 | 1.83 Mn |
| Jun 30, 2024 | 1.83 Mn |
| Mar 31, 2024 | 3.23 Mn |
| Mar 31, 2024 | 3.23 Mn |
| Dec 31, 2023 | 5.58 Mn |
| Dec 31, 2023 | 5.58 Mn |